Ying Kan

Title: **Innovative Contributions of Inventor Ying Kan in Oncology**

Introduction

Ying Kan is a noteworthy inventor based in Shanghai, China. He has made significant strides in the field of oncology through his innovative work on fully human monoclonal antibodies. With a total of two patents, his inventions are paving the way for advanced treatments for various tumors.

Latest Patents

Ying Kan's latest patents include groundbreaking discoveries that focus on the development of fully humanized monoclonal antibodies. The first patent, titled "Fully humanized anti-HER2 antibody, preparation method and use thereof," presents a fully human anti-HER2 monoclonal antibody. This invention includes specific amino acid sequences for both the heavy chain variable region and the light chain variable region, as outlined in SEQ ID NO: 6 and SEQ ID NO: 8. Moreover, it details the nucleotide sequences encoding the antibody, the expression vector, and the host cell necessary to produce the antibody, with applications in creating medicaments for tumor treatment.

The second patent, titled "Fully human monoclonal antibody to VEGF, preparation method and use thereof," showcases a fully human anti-VEGF monoclonal antibody. This antibody was developed using antibody phage display technology, resulting in a significantly higher affinity and stronger ability to inhibit tumor cell proliferation compared to existing options, like the humanized antibody bevacizumab. This innovation can be instrumental in the preparation of anti-tumor medicines.

Career Highlights

Ying Kan has built his career at Shanghai Biomabs Pharmaceuticals Co., Ltd., a company that focuses on developing novel antibody therapies. His contributions have not only enhanced the research landscape but also provided new therapeutic options for cancer treatment.

Collaborations

Throughout his career, Ying Kan has collaborated with several talented professionals in the field, including Chuan Li and Xin Tong. These partnerships have contributed to the successful development of his patents, enriching the collective knowledge within the company and the broader scientific community.

Conclusion

With his innovative patents and collaborations, Ying Kan stands out as a vital contributor to the field of oncology. His focus on fully human monoclonal antibodies has the potential to transform cancer treatments, highlighting the importance of continuous innovation in medical science.